Neurofibromatosis Research Program (NFRP)
Clinical Trial Award
Supports research with the potential to have a major impact on the treatment or management of neurofibromatosis (NF).
Pre-Application: May 23, 2019 5:00 pm ET
Application: June 6, 2019 11:59 pm ET
Exploration – Hypothesis Development Award
Supports the initial exploration of innovative, high-risk, high-gain concepts
and potentially groundbreaking concepts in NF research.
Pre-Application: May 23, 2019 5:00 pm ET
Application: June 6, 2019 11:59 pm ET
New Investigator Award
Supports the continued development of promising independent investigators
and/or the transition of established investigators from other research fields into a career in NF research
Pre-Application: May 23, 2019 5:00 pm ET
Application: June 6, 2019 11:59 pm ET
Early Investigator Research Award
Supports NF-focused research opportunities for individuals in the early stages of their careers.
Pre-Application: May 23, 2019 5:00 pm ET
Application: June 6, 2019 11:59 pm ET
Pharmacotherapies for Alcohol and Substance Abuse (PASA) ConsortiumThe goal of the PASA Consortium is to fund study applications for developing new medications that can be brought to therapeutic use to improve treatment outcomes for alcohol and substance use disorders (ASUD), especially as related to post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI).
PASA RFA #4a: Planning Grant
Small-cost and short-duration planning grant awarded to investigators concerning a specific compound or combination of compounds. Designed to determine the clinical development plan and associated clinical trials needed to advance the compound to FDA approval for ASUD treatment. The protocol for the first study will be developed as part of the planning grant and will be considered for funding and implementation by the PASA Consortium.
Letter of Intent for RFA 4a: Planning Grant - April 22, 2019
Full Application for RFA 4a: Planning Grant - June 3, 2019
PASA RFA #4b: Preclinical Study Implementation
Full study implementation awards for the conduct of proof-of-principle basic research to determine which compounds are most appropriate for human research trials.
Letter of Intent for RFA 4b: Preclinical Study - May 13, 2019
Full Application for RFA 4b: Preclinical Study - July 22, 2019
Autism Research Program (ARP)
Clinical Trial Award
Supports research with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (ASD).
Pre-Application: May 1, 2019 5:00 p.m. Eastern time (ET)
Invitation to Submit an Application: June 10, 2019
Application: August 8, 2019 11:59 p.m. ET
Idea Development Award
Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.
Pre-Application: May 1, 2019 5:00 p.m. Eastern time (ET)
Invitation to Submit an Application: June 10, 2019
Application: August 8, 2019 11:59 p.m. ET
Clinical Translational Research Award
Supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of ASD.
Pre-Application: May 1, 2019 5:00 p.m. Eastern time (ET)
Invitation to Submit an Application: June 10, 2019
Application: August 8, 2019 11:59 p.m. ET
Defense Medical Research and Development Program
Investigator Initiated Research Award
Must be relevant to at least one of the FY19 Clinical Research Intramural Initiative Investigator Initiated Research Award Focus areas:
Pre-Application (Preproposal): April 22, 2019
Preproposal is required; application submission is by invitation only.
Application: August 7, 2019